March 27, 2023

A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson’s disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having higher out-of-pocket costs and benefits similar to existing, less expensive drugs, only a small percentage of people with neurologic conditions are being treated with these new drugs, according to a study published in the November 30, 2022, online issue of Neurology.


Leave a Reply

Your email address will not be published. Required fields are marked *